Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications
Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications
复制标题
DOI：
10.1158/1078-0432.ccr-08-2743
复制
发表时间：
2010-02-01
影响因子：
11.5
通讯作者：
Brose, Marcia S.
中科院分区：
文献类型：
--
作者：
Keefe, Stephen M.;Cohen, Marc A.;Brose, Marcia S.
我们对分化型甲状腺癌（DTC）的分子病理生理学的理解在过去的10年里有了很大的发展。通过B-Raf和Akt的异常信号与DTC的肿瘤发生有关。此外，这些高度血管性肿瘤已被证明对血管内皮生长因子受体（VEGFR-2）的抑制敏感。多激酶抑制剂sorafenib、sunitinib、axitinib和motesanib的靶点包括VEGFR-2，很可能主要通过抑制内皮细胞发挥作用。然而，由于VEGFR-2在DTC细胞上表达，这些化合物可能具有直接的抗肿瘤作用。本文将讨论甲状腺癌的关键信号通路及其对靶向治疗的影响。临床癌症研究；16 (3);778 - 83。(c) 2010年aacr。
Our understanding of the molecular pathophysiology of differentiated thyroid cancer (DTC) has developed considerably over the last 10 years. Aberrant signaling through B-Raf and Akt has been implicated in the tumorigenesis of DTC. Moreover, these highly vascular tumors have proven to be sensitive to the inhibition of vascular endothelial growth factor receptor (VEGFR-2). It is likely that the multikinase inhibitors, sorafenib, sunitinib, axitinib, and motesanib, whose targets include VEGFR-2, exert their effects primarily through inhibition of endothelial cells. However, as VEGFR-2 is expressed on DTC cells, these compounds may have direct antitumor action. This review will discuss the key signaling pathways involved in thyroid cancer and their implications for targeted therapy. Clin Cancer Res; 16(3); 778-83. (C) 2010 AACR.